

Dr. Jürgen Schulze CEO & President Sysmex EMEA

IVD - EVOLVING BUSINESS ENVIRONMENT AND PRACTICES

The MedTech Europe exent

The MedTech Forum

bringing HealthTech stakeholders together

IVD - EVOLVING BUSINESS ENVIRONMENT AND PRACTICES IVD - EVOLUTION STATES | 1950 >> 2018 -> what's next?

IVD Industry Evolution

- 1950 1980: instrument technology, chemistry and biochemistry experts
- 1980 2018: integrated systems; software; workflow; productivity; immunology; molecular and genetic diagnostics; etc.
- → National reimbursement systems, time-to-market for innovation, financing models, silo mentality in healthcare systems, regulatory barriers, HTA barriers, other market entry barriers, etc.
- What's next ... here are some key words: Next Generation Sequencing (NGS); Big Data; CDx; AMR (antimicrobial resistance); new markers; new clinical value; preventive screening and early diagnosis; lab-on-chip; more B2C diagnostics; and many more ...

The MedTech Forum

bringling HealthTech stakeholders togethe

IVD Industry Evolution

The IVD innovation will be a challenge for our social security healthcare systems:

- The national healthcare systems are neither able nor prepared to manage the next innovation wave!
 - → Financial problems (perception: threat for sustainability of system)
 - Silo mentality within the systems (low outcome offentation)
 - > > Regulatory and other market entry barriers (many issues)

The IVD industry is shaping the advancement in healthcare. And we must create and implement the required new market entry models!!!

